354200 — NGeneBio Co Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩36bn
- KR₩32bn
- KR₩4bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 5,839 | 40,348 | 24,307 | 34,918 | 22,298 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 466 | 603 | 1,661 | 1,289 | 1,180 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 6,923 | 42,351 | 27,374 | 43,072 | 27,021 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 5,624 | 5,920 | 8,092 | 8,684 | 9,343 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 13,439 | 49,393 | 43,867 | 56,164 | 42,282 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 4,925 | 6,742 | 8,055 | 29,001 | 23,816 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 9,856 | 7,944 | 9,869 | 30,868 | 25,987 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
ESOP Debt Guarantee | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 3,583 | 41,449 | 33,998 | 25,297 | 16,295 |
Total Liabilities & Shareholders' Equity | 13,439 | 49,393 | 43,867 | 56,164 | 42,282 |
Total Common Shares Outstanding |